Enanta Pharmaceuticals Coverage Initiated by Analysts at FBR Capital Markets (ENTA)
Equities research analysts at FBR Capital Markets started coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note issued to investors on Thursday. The firm set an “outperform” rating on the stock.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.66% during mid-day trading on Thursday, hitting $39.19. The stock had a trading volume of 193,957 shares. Enanta Pharmaceuticals has a 52-week low of $18.21 and a 52-week high of $46.443. The stock has a 50-day moving average of $39.78 and a 200-day moving average of $38.35. The company has a market cap of $726.1 million and a P/E ratio of 21.24.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 11th. The company reported $2.61 earnings per share (EPS) for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. Enanta Pharmaceuticals’s revenue was up 2531.3% compared to the same quarter last year. Analysts expect that Enanta Pharmaceuticals will post $1.35 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $47.10 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Finally, analysts at Robert W. Baird downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, June 24th. They now have a $41.00 price target on the stock. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $44.03.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.